Randomized controlled trial to evaluate radiotherapy ± endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401

Japanese Journal of Clinical Oncology

Volumn 35, Issue 1, 2005, Pages 34-36

  Yokomizo, Akira ^a   Kawamoto, Hiroshi ^b   Nihei, Keiji ^c   Ishizuka, Naoki ^b   Kakehi, Yoshiyuki ^d   Tobisu, Ken Ichi ^e   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Endocrine therapy; Prostate cancer; Prostatectomy; PSA failure; Radiation

Indexed keywords

BICALUTAMIDE; GOSERELIN; HORMONE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; CANCER CENTER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MALE; MULTICENTER STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; ADULT; AGED; BIOASSAY; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; RADIATION DOSE; SURVIVAL RATE;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; ENDPOINT DETERMINATION; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 14944374004     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi007     Document Type: Article

References (13)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-7.
2. Carroll P. Rising PSA after a radical treatment. Eur Urol 2001; 40:Suppl 2:9-16.
3. International Union Against Cancer, Urological tumours. In: Sobin LH, Wittekind C, editors. TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss 1997;170-3.
4. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:731-6.
5. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-50.
6. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 2000;48:369-75.
7. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-82.
8. Shoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982;38:163-70.
9. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12® Health Survey (With a Supplement Documenting Version 1). Lincoln, RI: Quality Metric Incorporated, 2002.
10. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1999;36:1002-12.
11. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998;51:1045-53.
12. Kakehi Y, Kamoto T, Ogawa O, Arai Y, Litwin MS, Suzukamo Y, et al. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. Int J Clin Oncol 2002;7:306-11.
13. Suzukamo Y, Kakehi Y, Kamoto T, Arai Y, Ogawa O, Fukuhara S. Translation and adaptation of the UCLA prostate cancer index for use in Japan. Nippon Hinyokika Gakkai Zasshi 2002;93:659-68 (in Japanese).